Following today's 39% decline amid FDA briefing documents on its lorcaserin diet pill, shares of Arena Pharma (Nasdaq: ARNA) are ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE